The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
Abstract
For all its imperfections at treating Parkinson's disease (PD), orally‐administered levodopa (l‐dopa) can be regarded as the “platinum” standard of PD therapeutics for its impact on disability and discomfort and its cost‐effectiveness. The past half‐century has confirmed that the typical l‐dopa–treated patient gains improvement for most Parkinsonian features, presumably by conversion of this amino acid into dopamine in the striatum. However, fundamental questions remain as to its full mechanism of action and how adverse reactions evolve. Various aspects of clinical phenomenology associated with chronic l‐dopa use (such as dyskinesias and the long‐duration anti‐Parkinsonian response) present a continuing challenge for better understanding of its pharmacology. The pharmacokinetics of l‐dopa tend to predict some of problems that can emerge during chronic therapy, which can be linked with its irregular uptake and marked dose‐by‐dose variability in plasma concentrations. Several new pharmaceutical approaches are targeted at the unique physiology of l‐dopa uptake and are likely to improve the consistency of its anti‐Parkinsonian effect. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Handbook of Experimental Pharmacology, vol 14.
Freedman, A. D. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.03650020118031 · Cited by 774
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationGastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiology
Edwards, L. L., Quigley, E. M. M., & Pfeiffer, R. F. (1992) · Neurology · doi:10.1212/wnl.42.4.726 · Cited by 359
Nutl, J. G., & Fellman, J. H. (1984) · Clinical Neuropharmacology · doi:10.1097/00002826-198403000-00002 · Cited by 356
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Self-citationTanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (1999) · NeuroReport · doi:10.1097/00001756-199902250-00034 · Cited by 302
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Gastric emptying time and gastric motility in patients with Parkinson's disease
Hardoff, R., Sula, M., Tamir, A., Soil, A., Front, A., Badarna, S., Honigman, S., & Giladi, N. (2001) · Movement Disorders · doi:10.1002/mds.1203 · Cited by 248
Muenter, M. D., & Tyce, G. M. (1971) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07667-0 · Cited by 248
Hauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., Ondo, W., O'Connell, M., & Gupta, S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70025-5 · Cited by 210
Hornykiewicz, O. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5741-y · Cited by 184
Leenders, K. L., Poewe, W. H., Palmer, A. J., Brenton, D. P., & Frackowiak, R. S. J. (1986) · Annals of Neurology · doi:10.1002/ana.410200212 · Cited by 172
The site of dopamine formation in rat striatum after L-dopa administration.
Hefti, F. F., Melamed, E., & Wurtman, R. J. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32511-5 · Cited by 166
Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease: An Update
Nyholm, D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00001 · Cited by 164
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh, K. C., August, T. F., Bush, D., Lasseter, K. C., Musson, D. G., Schwartz, S. E., Smith, M. E., & Titus, D. C. (1989) · PubMed · Cited by 161
(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-157_5 · Cited by 148
Cenci, M. A., Tranberg, A., Andersson, M., & Hilbertson, A. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00294-8 · Cited by 131
Evolution of the response to levodopa during the first 4 years of therapy
Nutt, J. G., Carter, J. H., Lea, E. S., & Sexton, G. J. (2002) · Annals of Neurology · doi:10.1002/ana.10189 · Cited by 130
Robertson, D., Wood, N., Everest, H., Monks, K., Waller, D., Renwick, A., & George, C. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03506.x · Cited by 117
Tremblay, P.-L., Bédard, M., Langlois, D., Blanchet, P. J., Lemay, M., & Parent, M. J. (2010) · Experimental Brain Research · doi:10.1007/s00221-010-2372-6 · Cited by 96
Episodic unresponsiveness to single doses of L‐dopa in parkinsonian fluctuators
Melamed, E., Bitton, V., & Zelig, O. (1986) · Neurology · doi:10.1212/wnl.36.1.100 · Cited by 91
Nyholm, D., Lennernäs, H., Gomes–Trolin, C., & Aquilonius, S. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00006 · Cited by 91
Anderson, E., & Nutt, J. G. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.03.014 · Cited by 90
Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease
Contin, M., Riva, R., Albani, F., & Baruzzi, A. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630060-00004 · Cited by 73
The influence of levodopa on gastric emptying in man.
Robertson, D., Renwick, A., Wood, N., Cross, N. C. P., Macklin, B., Fleming, J. S., Waller, D., & George, C. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03601.x · Cited by 73
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics
Kompoliti, K., Adler, C. H., Raman, R., Pincus, J. H., Leibowitz, M. T., Ferry, J. J., Blasucci, L. M., Caviness, J. N., Leurgans, S. E., Chase, W. M., et al. (2002) · Neurology · doi:10.1212/wnl.58.9.1418 · Cited by 72
l-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system
Misu, Y., Kitahama, K., & Goshima, Y. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00325-x · Cited by 70
Loss of long-duration response to levodopa over time in PD
Zappia, M., Oliveri, R. L., Montesanti, R., Rizzo, M., Bosco, D., Plastino, M., Crescibene, L., Bastone, L., Aguglia, U., Gambardella, A., et al. (1999) · Neurology · doi:10.1212/wnl.52.4.763 · Cited by 65
The subacute levodopa test for evaluating long‐duration response in parkinson's disease
Quattrone, A., Zappia, M., Aguglia, U., Branca, D., Colao, R., Montesanti, R., Nicoletti, G., Palmieri, A., Parlato, G., & Rizzo, M. (1995) · Annals of Neurology · doi:10.1002/ana.410380308 · Cited by 65
Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease
LeWitt, P. A., Huff, F. J., Hauser, R. A., Chen, D., Lissin, D., Zomorodi, K., & Cundy, K. C. (2013) · Movement Disorders · doi:10.1002/mds.25742 · Cited by 59
Self-citationHelicobacter pylori eradication for Parkinson's disease
Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008453.pub2 · Cited by 56
Kaakkola, S. (2010) · International review of neurobiology · doi:10.1016/b978-0-12-381326-8.00009-0 · Cited by 54
Othman, A. A., & Dutta, S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12324 · Cited by 50
Dual effects of l-DOPA on nigral dopaminergic neurons
Guatteo, E., Yee, A. G., McKearney, J. W., Cucchiaroni, M. L., Armogida, M., Berretta, N., Mercuri, N. B., & Lipski, J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.02.009 · Cited by 49
Motor fluctuations and Helicobacter pylori in Parkinson’s disease
Rahne, K.-E., Tagesson, C., & Nyholm, D. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7089-6 · Cited by 49
Pharmacokinetic‐pharmacodynamic crossover comparison of two levodopa extension strategies
LeWitt, P. A., Jennings, D. L., Lyons, K. E., Pahwa, R., Rabinowicz, A. L., Wang, J., Guarnieri, M., Hubble, J. P., & Murck, H. (2009) · Movement Disorders · doi:10.1002/mds.22587 · Cited by 47
Self-citationNarożańska, E., Białecka, M. A., Adamiak-Giera, U., Gawronska-Szklarz, B., Sołtan, W., Schinwelski, M. J., Robowski, P., Madalinski, M. H., & Sławek, J. W. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000037 · Cited by 46
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt, P. A., Nelson, M. V., Berchou, R. C., et al. (1989) · PubMed · Cited by 44
Self-citationNelson, M. V., Berchou, R. C., LeWitt, P. A., Kareti, D., & Galloway, M. P. (1990) · Neurology · doi:10.1212/wnl.40.1.70 · Cited by 38
Self-citationAureli, C., Cassano, T., Masci, A., Francioso, A., Martire, S., Cocciolo, A., Chichiarelli, S., Romano, A., Gaetani, S., Mancini, P., et al. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23318 · Cited by 34
Chan, P. L. S., Nutt, J. G., & Holford, N. H. G. (2005) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-005-0039-x · Cited by 33
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa
Cedarbaum, J. M., Kutt, H., Dhar, A. K., Watkins, S., & MCDOWELL, F. H. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198604000-00006 · Cited by 33
Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients
TRIGGS, E. J., Charles, B. G., Contin, M., et al. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050161 · Cited by 32
LeWitt, P. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a0feba · Cited by 28
Self-citationOstock, C. Y., Lindenbach, D., Goldenberg, A. A., Kampton, E. B., & Bishop, C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.009 · Cited by 27
Chen, C., Cowles, V. E., Sweeney, M. L., Stolyarov, I. D., & Illarioshkin, S. N. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31824523de · Cited by 26
Iron‐Mediated Oxidation of 3,4‐Dihydroxyphenylalanine to an Excitotoxin
Newcomer, T. A., Rosenberg, P. A., & Aizenman, E. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041742.x · Cited by 26
L‐dopa decarboxylation in chronically treated patients
Ward, C. D., Trombley, I. K., Calne, D. B., & Kopin, I. J. (1984) · Neurology · doi:10.1212/wnl.34.2.198 · Cited by 24
Nelson, M. V., Berchou, R. C., LeWitt, P. A., et al. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198904000-00002 · Cited by 22
Self-citationFactors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease
Stocchi, F., & Marconi, S. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181de8924 · Cited by 21
King, J. M., Muthian, G., Mackey, V., et al. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.08.008 · Cited by 20
Ebihara, K., Ishida, Y., Takeda, R., Abe, H., Matsuo, H., Kawai, K., Magata, Y., & Nishimori, T. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.03.087 · Cited by 15
DOPA as a Neurotransmitter Candidate
Misu, Y., & Goshima, Y. (2005) · doi:10.1201/9781420023329-9 · Cited by 3
Cited by
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Levodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Zhang, B., Yan, W., Zhu, Y., Yang, W., Le, W., Chen, B., Zhu, R., & Cheng, L. (2018) · Advanced Materials · doi:10.1002/adma.201705694 · Cited by 113
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease
Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5157 · Cited by 84
Metadata
- Authors
- LeWitt, P. A.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-12
- Volume
- 30
- Issue
- 1
- Pages
- 64-72
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1955911053
- Cited by
- 391
- References
- 62
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.